← Scroll for more →
Financial Statements — BLSM
Balance Sheet
(in millions USD)| Metric | Q2 2026 |
|---|---|
| Cash & Equivalents | 95.38 |
| Total Current Assets | 100.97 |
| Property, Plant & Equipment | 1.49 |
| Total Non-current Assets* | 23.16 |
| Total Assets | 124.13 |
| Accounts Payable | 9.19 |
| Total Current Liabilities | 18.62 |
| Total Non-current Liabilities* | 23.47 |
| Total Liabilities | 42.09 |
| Retained Earnings | (179.79) |
| Total Stockholder Equity | (174.78) |
← Scroll for more columns →
* Derived from reported values
Income Statement
(in millions USD) (except per-share rows)| Metric | Q2 2026 |
|---|---|
| Research & Development | 21.36 |
| Selling, General & Admin | 3.32 |
| Total Operating Expenses | 24.67 |
| Operating Income | (24.67) |
| Net Income | (23.76) |
| Basic EPS | (8.75) |
| Diluted EPS | (8.75) |
← Scroll for more columns →
Cash Flow Statement
(in millions USD)| Metric | Q2 2026 |
|---|---|
| Operating Cash Flow | (44.17) |
| Capital Expenditures | 0.01 |
| Free Cash Flow* | (44.19) |
| Investing Cash Flow | (0.01) |
| Financing Cash Flow | 2.88 |
← Scroll for more columns →
* Derived from reported values